Brokerages Set Repligen Co. (NASDAQ:RGEN) Target Price at $178.64

Shares of Repligen Co. (NASDAQ:RGEN) have been assigned a consensus recommendation of “Moderate Buy” from the fourteen research firms that are covering the stock, MarketBeat reports. Six analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The average 1-year price target among analysts that have covered the stock in the last year is $178.64.

A number of research firms have issued reports on RGEN. Canaccord Genuity Group started coverage on shares of Repligen in a research note on Tuesday, December 17th. They set a “hold” rating and a $165.00 price objective for the company. Evercore ISI began coverage on shares of Repligen in a report on Tuesday, March 18th. They set an “in-line” rating and a $155.00 price target on the stock. TD Cowen began coverage on Repligen in a research note on Monday, February 10th. They issued a “buy” rating and a $200.00 price target for the company. HC Wainwright reiterated a “buy” rating and set a $180.00 target price on shares of Repligen in a research report on Friday, February 21st. Finally, Canaccord Genuity Group lifted their target price on shares of Repligen from $165.00 to $170.00 and gave the company a “hold” rating in a research report on Friday, February 21st.

Repligen Stock Performance

Shares of RGEN stock opened at $133.41 on Friday. The business’s fifty day simple moving average is $154.21 and its 200-day simple moving average is $148.19. Repligen has a 12-month low of $113.50 and a 12-month high of $184.98. The company has a market cap of $7.49 billion, a PE ratio of -261.59, a PEG ratio of 4.54 and a beta of 0.95. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings results on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.41 by $0.03. The business had revenue of $167.55 million during the quarter, compared to analysts’ expectations of $167.58 million. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. Analysts expect that Repligen will post 1.72 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Margaret Pax purchased 250 shares of the company’s stock in a transaction dated Monday, March 17th. The stock was acquired at an average price of $150.69 per share, with a total value of $37,672.50. Following the purchase, the director now directly owns 1,043 shares in the company, valued at approximately $157,169.67. This represents a 31.53 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 1.20% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Price T Rowe Associates Inc. MD boosted its stake in Repligen by 11.6% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 7,136,054 shares of the biotechnology company’s stock worth $1,027,165,000 after buying an additional 743,815 shares during the period. Point72 Asset Management L.P. grew its position in Repligen by 183.1% in the 4th quarter. Point72 Asset Management L.P. now owns 918,623 shares of the biotechnology company’s stock valued at $132,227,000 after acquiring an additional 594,189 shares in the last quarter. Groupama Asset Managment boosted its stake in shares of Repligen by 12,321.0% in the fourth quarter. Groupama Asset Managment now owns 403,932 shares of the biotechnology company’s stock valued at $58,142,000 after purchasing an additional 400,680 shares during the period. Alyeska Investment Group L.P. purchased a new stake in Repligen during the 4th quarter worth approximately $53,428,000. Finally, Raymond James Financial Inc. acquired a new position in shares of Repligen in the fourth quarter worth $52,492,000. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.